NDAORALTABLETPriority Review
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Nuclear Export Inhibitors
Pharmacologic Class:
Nuclear Export Inhibitor
Clinical Trials (5)
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Started Jul 2026
62 enrolled
Relapse Multiple MyelomaRefractory Multiple Myeloma
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Started May 2026
26 enrolled
MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Started Mar 2026
20 enrolled
Multiple Myeloma
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Started Nov 2025
228 enrolled
Relapsed or Refractory Multiple Myeloma
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Started Apr 2024
58 enrolled
MyelofibrosisModerate ThrombocytopeniaMild Thrombocytopenia
Loss of Exclusivity
LOE Date
Aug 14, 2035
114 months away
Patent Expiry
Aug 14, 2035
Exclusivity Expiry
Dec 18, 2027
Company
Mthera Pharma
Korea - Seoul